Luca Issi
Stock Analyst at RBC Capital
(3.50)
# 848
Out of 5,173 analysts
221
Total ratings
46.76%
Success rate
4.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Upgrades: Outperform | $11 → $35 | $15.92 | +119.85% | 8 | Mar 9, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Sector Perform | $9 → $15 | $13.11 | +14.42% | 8 | Mar 3, 2026 | |
| ASND Ascendis Pharma | Maintains: Outperform | $250 → $275 | $218.06 | +26.11% | 5 | Mar 3, 2026 | |
| ARGX argenx SE | Maintains: Outperform | $925 → $890 | $681.85 | +30.53% | 4 | Feb 27, 2026 | |
| BEAM Beam Therapeutics | Maintains: Sector Perform | $22 → $26 | $25.17 | +3.30% | 8 | Feb 25, 2026 | |
| MRNA Moderna | Maintains: Sector Perform | $25 → $30 | $51.28 | -41.50% | 19 | Feb 17, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $500 → $465 | $306.66 | +51.63% | 29 | Jan 20, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $82 → $95 | $70.79 | +34.20% | 11 | Dec 17, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Outperform | $52 → $80 | $56.67 | +41.17% | 11 | Dec 11, 2025 | |
| WVE Wave Life Sciences | Upgrades: Outperform | $9 → $27 | $11.62 | +132.36% | 6 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $7 → $10 | $6.89 | +45.14% | 3 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $57 → $28 | $28.11 | -0.39% | 1 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $85 → $8 | $11.27 | -29.02% | 8 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $42 → $50 | $46.88 | +6.66% | 15 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $19 | $8.34 | +127.82% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $30 | $17.87 | +67.88% | 4 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $2.44 | +309.84% | 9 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $21 → $18 | $17.57 | +2.45% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $5.54 | +261.01% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $2 | $0.34 | +497.01% | 6 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $8.10 | +109.88% | 1 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $7.65 | +69.93% | 6 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $35 | $9.23 | +279.20% | 7 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $54.78 | +27.78% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $49.25 | +15.74% | 1 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $2.40 | +66.67% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $77 | $20.27 | +279.87% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.86 | +652.69% | 5 | Aug 7, 2024 |
uniQure
Mar 9, 2026
Upgrades: Outperform
Price Target: $11 → $35
Current: $15.92
Upside: +119.85%
Intellia Therapeutics
Mar 3, 2026
Maintains: Sector Perform
Price Target: $9 → $15
Current: $13.11
Upside: +14.42%
Ascendis Pharma
Mar 3, 2026
Maintains: Outperform
Price Target: $250 → $275
Current: $218.06
Upside: +26.11%
argenx SE
Feb 27, 2026
Maintains: Outperform
Price Target: $925 → $890
Current: $681.85
Upside: +30.53%
Beam Therapeutics
Feb 25, 2026
Maintains: Sector Perform
Price Target: $22 → $26
Current: $25.17
Upside: +3.30%
Moderna
Feb 17, 2026
Maintains: Sector Perform
Price Target: $25 → $30
Current: $51.28
Upside: -41.50%
Alnylam Pharmaceuticals
Jan 20, 2026
Maintains: Outperform
Price Target: $500 → $465
Current: $306.66
Upside: +51.63%
Ionis Pharmaceuticals
Dec 17, 2025
Maintains: Outperform
Price Target: $82 → $95
Current: $70.79
Upside: +34.20%
Arrowhead Pharmaceuticals
Dec 11, 2025
Maintains: Outperform
Price Target: $52 → $80
Current: $56.67
Upside: +41.17%
Wave Life Sciences
Dec 9, 2025
Upgrades: Outperform
Price Target: $9 → $27
Current: $11.62
Upside: +132.36%
Dec 8, 2025
Maintains: Sector Perform
Price Target: $7 → $10
Current: $6.89
Upside: +45.14%
Nov 20, 2025
Downgrades: Sector Perform
Price Target: $57 → $28
Current: $28.11
Upside: -0.39%
Nov 13, 2025
Downgrades: Sector Perform
Price Target: $85 → $8
Current: $11.27
Upside: -29.02%
Nov 11, 2025
Maintains: Sector Perform
Price Target: $42 → $50
Current: $46.88
Upside: +6.66%
Nov 7, 2025
Maintains: Outperform
Price Target: $17 → $19
Current: $8.34
Upside: +127.82%
Nov 6, 2025
Maintains: Outperform
Price Target: $23 → $30
Current: $17.87
Upside: +67.88%
May 14, 2025
Reiterates: Outperform
Price Target: $10
Current: $2.44
Upside: +309.84%
May 8, 2025
Maintains: Sector Perform
Price Target: $21 → $18
Current: $17.57
Upside: +2.45%
Mar 25, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $5.54
Upside: +261.01%
Mar 18, 2025
Reiterates: Sector Perform
Price Target: $2
Current: $0.34
Upside: +497.01%
Mar 18, 2025
Initiates: Outperform
Price Target: $17
Current: $8.10
Upside: +109.88%
Mar 17, 2025
Maintains: Outperform
Price Target: $11 → $13
Current: $7.65
Upside: +69.93%
Mar 3, 2025
Maintains: Outperform
Price Target: $39 → $35
Current: $9.23
Upside: +279.20%
Feb 20, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $54.78
Upside: +27.78%
Jan 21, 2025
Reiterates: Outperform
Price Target: $57
Current: $49.25
Upside: +15.74%
Dec 13, 2024
Maintains: Sector Perform
Price Target: $5 → $4
Current: $2.40
Upside: +66.67%
Nov 6, 2024
Reiterates: Outperform
Price Target: $77
Current: $20.27
Upside: +279.87%
Aug 7, 2024
Reiterates: Outperform
Price Target: $14
Current: $1.86
Upside: +652.69%